IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 68, Issue 6, 2013, Pages 796-802

  Kim, J ^a,b   Park, M R ^a,b   Kim, D S ^a,b   Lee, J O ^b   Maeng, S H ^a   Cho, S Y ^a   Han, Y ^b   Ahn, K ^a,b   Jin, D K ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

anaphylaxis; idursulfase; mucopolysaccharidosis; urticaria

Indexed keywords

IDURONATE 2 SULFATASE; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY;

ADOLESCENT; ADULT; ANAPHYLAXIS; ANTIBODY DETECTION; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; ELECTROPHORESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REPLACEMENT; EOSINOPHIL COUNT; HUMAN; HUNTER SYNDROME; IMMUNOBLOTTING; MALE; PRESCHOOL CHILD; PRICK TEST; PRIORITY JOURNAL; SCHOOL CHILD; SEQUENCE HOMOLOGY; WESTERN BLOTTING;

ADOLESCENT; ADULT; ANAPHYLAXIS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG HYPERSENSITIVITY; ENZYME REPLACEMENT THERAPY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IDURONATE SULFATASE; IMMUNOGLOBULIN E; INFUSIONS, INTRAVENOUS; MALE; MUCOPOLYSACCHARIDOSIS II; RISK FACTORS; SKIN TESTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878114186     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12155     Document Type: Article

References (24)

1. Muenzer J,. Overview of the mucopolysaccharidoses. Rheumatology (Oxford) 2011; 50 (Suppl 5): v4-v12.
2. Schulze-Frenking G, Jones SA, Roberts J, Beck M, Wraith JE,. Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II. J Inherit Metab Dis 2011; 34: 203-208.
3. Burrow TA, Leslie ND,. Review of the use of idursulfase in the treatment of mucopolysaccharidosis II. Biologics 2008; 2: 311-320.
4. Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006; 8: 465-473.
5. Okuyama T, Tanaka A, Suzuki Y, Ida H, Tanaka T, Cox GF, et al. Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II). Mol Genet Metab 2010; 99: 18-25.
6. Muenzer J, Beck M, Giugliani R, Suzuki Y, Tylki-Szymanska A, Valayannopoulos V, et al. Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey. Genet Med 2011; 13: 102-109.
7. Muenzer J, Beck M, Eng CM, Giugliani R, Harmatz P, Martin R, et al. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med 2011; 13: 95-101.
8. Burton BK, Whiteman DA,. Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS). Mol Genet Metab 2011; 103: 113-120.
9. Jones SA, Almassy Z, Beck M, Burt K, Clarke JT, Giugliani R, et al. Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis 2009; 32: 534-543.
10. Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, et al. Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117: 391-397.
11. Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P,. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 2002; 57: 45-51.
12. Barbaud A, Goncalo M, Bruynzeel D, Bircher A,. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Derm 2001; 45: 321-328.
13. Mirakian R, Ewan PW, Durham SR, Youlten LJ, Dugue P, Friedmann PS, et al. BSACI guidelines for the management of drug allergy. Clin Exp Allergy 2009; 39: 43-61.
14. Laemmli UK,. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
15. Gomez E, Torres MJ, Mayorga C, Blanca M,. Immunologic evaluation of drug allergy. Allergy Asthma Immunol Res 2012; 4: 251-263.
16. Pichler WJ,. Adverse side-effects to biological agents. Allergy 2006; 61: 912-920.
17. Abramowicz D, Crusiaux A, Goldman M,. Anaphylactic shock after retreatment with OKT3 monoclonal antibody. N Engl J Med 1992; 327: 736.
18. Clarke LA, Wraith JE, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics 2009; 123: 229-240.
19. Rosenberg M, Kingma W, Fitzpatrick MA, Richards SM,. Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood 1999; 93: 2081-2088.
20. Clarke LA,. Idursulfase for the treatment of mucopolysaccharidosis II. Expert Opin Pharmacother 2008; 9: 311-317.
21. Wilson PJ, Morris CP, Anson DS, Occhiodoro T, Bielicki J, Clements PR, et al. Hunter syndrome: isolation of an iduronate-2-sulfatase cDNA clone and analysis of patient DNA. Proc Natl Acad Sci U S A 1990; 87: 8531-8535.
22. Blanca M, Mayorga C, Torres MJ, Warrington R, Romano A, Demoly P, et al. Side-chain-specific reactions to betalactams: 14 years later. Clin Exp Allergy 2002; 32: 192-197.
23. Vultaggio A, Matucci A, Nencini F, Pratesi S, Parronchi P, Rossi O, et al. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 2010; 65: 657-661.
24. Campi P, Benucci M, Manfredi M, Demoly P,. Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-alpha antagonists. Curr Opin Allergy Clin Immunol 2007; 7: 393-403.